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Abstract: This review focuses on emerging viral and bacterial infections in the human  central 
nervous system (CNS) that are responsible for significant global morbidity and mortality. 
These infections include those responsible for acute neurological disease such as meningitis 
and encephalitis as well those associated with chronic neurodegenerative conditions. Recent 
changes in climate conditions and pollution have been precipitating factors leading to the emer-
gence of many of these pathogenic organisms. In addition, increased urbanization, global travel, 
life span, and exposure to new vectors have promoted the organisms’ spread across the globe. 
 Categorization of many of these organisms includes identification of new species, recognition 
of new tropism to the CNS, spread into naïve demographic areas, increased human contact with 
zoonotic repositories including insect vectors, and reemergence of well-known organisms. These 
mechanisms are highlighted for the different organisms included in this review. Other mecha-
nisms for CNS emergence such as genetic mutation of the organisms and immunosuppression 
and/or immunosenescence of the host are addressed. Viral and bacterial infections in chronic 
neurodegenerative diseases traditionally not thought to be infectious are considered. Although 
this review cannot be all-inclusive, the organisms included represent a sampling of extremely 
important microbes and their role in CNS pathogenesis in the twenty-first century.
Keywords: viruses, bacteria, central nervous system, emergence
Global emergence of central nervous system (CNS) associated infectious disease 
is  currently being recognized. Pathogenic viruses, bacteria, fungi, and protozoa are 
infecting the human CNS resulting in widespread disease. Global variances includ-
ing climate changes and pollution have led to changes in these pathogenic organisms. 
Increased human urbanization, global travel, and life span have led to increased expo-
sure to drug-resistant viral and bacterial strains, as well as to new strains, often through 
increased zoonotic and vector contact. This review focuses on viral and bacterial 
infections in the CNS that are causing and/or associated with significant morbidity and 
mortality in acute neurological disease and chronic neurodegenerative conditions. 
As research is uncovering associations of viral and bacterial infections with major 
CNS diseases traditionally not considered caused or exacerbated by infectious enti-
ties, we have included these as emerging infections. In this way, this review extends 
our awareness and understanding of the involvement of infection in the concomitant 
pathogenesis of CNS disease.
Viruses
Prior studies and reviews by others have highlighted many viruses (see Table 1) 
contributing to the new emergence of infection in the human CNS.1–3 Categorization 
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of these viruses includes identif ication of new viral 
species, recognition of new viral tropism to the CNS, 
viral spread into naïve demographic areas, increased 
human contact with zoonotic repositories including insect 
vectors, and reemergence of well-known viral species. 
Other mechanisms for CNS emergence include genetic 
mutation of existing viruses and immunosuppression and/
or immunosenescence of the host. Some of these viruses 
may be associated with specific disease states such as John 
Cunningham virus (JC virus) and progressive multifocal 
leukoencephalopathy, while others, like West Nile virus, 
appear to play a role in meningitis, encephalitis, or 
meningoencephalitis.
Identification of new viral species
Henipaviruses (Hendra and Nipah) in the family Paramyxo-
viridae were first identified in the mid to late 1990s.4,5 
Hendra infection was first identified in the aseptic men-
ingitis and frank encephalitis deaths of a few Australian 
individuals who had been in close contact with horses.4 
Hendra was originally thought to be an equine Morbil-
livirus but was subsequently reclassified with Nipah virus 
into the  Henipaviruses. Nipah virus is the more frequently 
encountered virus of the  Henipaviruses, and most cases of 
emergence have resulted from this infection. Nipah was 
identified originally in pig farmers in Malaysia in 1998 and 
resulted in acute encephalitis that proved fatal in .30% of 
cases.5,6 Common neurological symptoms include fever, 
headache, segmental myoclonus, reduced tendon reflexes, 
nuchal rigidity, and seizures.7,8  Interestingly, with Nipah 
infection, 3% of  individuals developed late-onset encepha-
litis that did not initially have neurological symptoms, and 
8% of acute encephalitic patients had recurrent or relaps-
ing encephalitis on an average of 8 months following acute 
disease.9 Of the fatal cases of Nipah virus infection, analysis 
of brain tissues at autopsy suggested the virus spreads to the 
CNS from the bloodstream. Following this spread, there is 
subsequent multifocal vasculitis, multicentric thrombosis, 
and direct neuronal infection.10 Outbreaks of Nipah virus 
encephalitis also have appeared in India and Bangladesh 
with high mortality; however, these are thought to be miti-
gated by a different source of infection, secretions from the 
fruit bat.11 Newer studies suggest that transmission now can 
occur from person to person.12 Regardless of the mode of 
transmission, infection with this family of viruses exacts 
a large toll on the human population, thus keeping these 
viruses near the top of emerging CNS infectious threats. 
There is no effective treatment for these viruses other than 
supportive care.
Viruses emerging in new  
demographic areas
Numerous viruses have emerged recently in new demo-
graphic areas around the world. Some of the most notable 
are Enterovirus 71, West Nile virus, Japanese encephalitis 
virus, and Chikungunya virus. Interestingly, other than for 
Enterovirus 71, one commonality of these viruses is that they 
are insect vector borne.
Enterovirus 71
Enterovirus 71 (EV71) is a member of the family Picornaviridae 
and is one of the most important  regarding widespread 
demographic emergence and involvement with CNS dis-
ease. This is particularly the case in children in which 
hand-foot-mouth disease is manifest most often  following 
this infection.2 Brainstem encephalitis, acute flaccid paraly-
sis, and aseptic meningitis have been recognized as sequelae 
in these children, although this may vary with different 
outbreaks.13,14 EV71 was first isolated in California in the 
late 1960s, but since then there have been numerous out-
breaks worldwide with some of the most severe occurring 
in Southeast Asia and the Pacific Rim nations.15,16 During 
hand-foot-mouth disease epidemics, CNS disease is fre-
quently encountered, and symptoms may include systemic 
features such as fever, mouth ulcers, cough, vomiting, and 
irritability.17 Treatment for EV71 infections is principally 
supportive. EV71 and mutated EV71 viruses appear to be 
one of our greatest threats with emerging Picornaviridae, 
Table 1 Proposed viruses emerging in central nervous system 
disease
Virus Condition/disease  
association
Viral family
Henipah virus  
(Hendra and Nipah)
Encephalitis/meningitis Paramyxoviridae
Enterovirus 71 Encephalitis/meningitis/  
flaccid paralysis
Picornaviridae
west Nile virus Encephalitis/meningitis Flaviviridae
Japanese  
encephalitis virus
Encephalitis Flaviviridae
Chikungunya virus Encephalitis/meningitis Togaviridae
Influenza virus Encephalitis/schizophrenia Orthomyxoviridae
JC virus Progressive Multifocal 
Leukoencephalopathy (PML)
Polyomaviridae
Human  
Herpesvirus 6
Encephalitis/epilepsy/ 
multiple sclerosis
Herpesviridae
Herpes simplex  
virus 1
Encephalitis/Alzheimer’s  
disease
Herpesviridae
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and thus, there is an increasing need for effective and specific 
vaccines.15
west Nile virus
West Nile virus (WNV), a member of the Flaviviridae  family, 
was first isolated in the West Nile province of Uganda in the 
1930s.2 The virus has been reported in Central America, the 
Caribbean, Europe, the Middle East, Africa, India, Asia, 
and Australia.18,19 No cases of WNV encephalitis were 
recognized in the United States until the late 1990s yet the 
virus has spread rapidly; today, most states have reported 
cases of human disease.20,21 Culex genus mosquitos are the 
principal vectors for WNV, and resident bird species are the 
major host reservoir thought to be responsible for spread of 
the virus.22 The majority of WNV infections are acute and 
asymptomatic, with approximately 20% resulting in West 
Nile Fever and approximately 1% leading to neuroinvasive 
disease.23 Upon neuroinvasion, encephalitis, meningitis, and 
acute flaccid paralysis may occur. Individuals 60 years of 
age or older and afflicted with other conditions, including 
diabetes and hypertension, are more susceptible to develop-
ing encephalitis.24 Encephalitis symptoms include mental 
status change, headache, fever, and Parkinsonian movement 
disorders. Meningitis symptoms typically consist of head-
ache and fever, photophobia, and, at times, nerve palsies. 
 Individuals exhibiting acute flaccid paralysis also show 
signs of encephalitis and Parkinsonism change with deficits 
in nerve conduction; although some of these patients may 
regain some strength over time, others may not recover.25 
The clinical course is variable for WNV infections; patients 
convalescing from meningitis may continue to have persis-
tent headaches and fatigue, while those with encephalitis 
may manifest persistent neurologic deficits.26 There is no 
specific treatment other than supportive care for infected 
individuals.
Japanese encephalitis virus
Similar to WNV, the Japanese encephalitis virus (JEV) is 
a member of the Flaviviridae, and is transmitted by Culex 
genus mosquitos.27 Natural reservoirs for this virus are 
pigs, egrets, and herons. JEV was first identified in Japan 
in the 19th century and has spread over decades into China, 
Southeast Asia, India, and the Indian subcontinent, New 
Guinea, and Australia.27 The emergence of JEV can be 
attributed to increased population growth in endemic areas 
and occupational exposure with rice and pig farming pre-
senting increased risk of vector-borne infection.27 JEV often 
is asymptomatic, but may cause severe acute encephalitis, 
which can be fatal.28 In this regard, 10,000 deaths or more 
annually have been attributed to JEV infections and their role 
in acute viral encephalitis.29,30 Symptoms range from nuchal 
rigidity, severe rigors, and hemiparesis to nausea, headache, 
and fever. Although there is no specific therapy for JEV, there 
is a live-attenuated vaccine, and new candidate vaccines are 
being developed.30
Chikungunya virus
Chikungunya virus (CHIKV), which belongs to the family 
Togaviridae, is an arbovirus transmitted by the Aedes 
mosquito (eg, Aedes aegypti). CHIKV was first isolated in 
Tanzania and subsequently in other areas of sub-Saharan 
Africa, India, and Southeast Asia.31 The virus is considered 
an encephalitic and arthritic virus. Neurological diseases 
attributed to CHIKV include encephalitis, meningitis, 
encephalomyelitis, Guillain-Barré-like syndrome, and acute 
flaccid paralysis.32–35 Experimental evidence from neonatal 
and adult mice in which the interferon α/β receptor was 
knocked out to prevent interferon signaling suggests that 
virus inoculated peripherally may enter the choroid plexus 
of the brain following a viremia.36 The association of this 
virus with CNS disease in humans is thought to arise due to 
increased geographical distribution by population mobility 
from endemic areas to naïve areas and possibly by com-
mercial trade of materials containing water-borne mosquito 
larvae.37 In addition, there is evidence from an outbreak of 
this infection on the island of La Reunion in the Indian Ocean 
in 2005–2006 that the virus underwent mutation to infect 
a second Aedes species, Aedes albopictus.31,38–41 As Aedes 
albopictus mosquitos are found in urban areas of Europe and 
the United States, there is increased risk for this infection to 
spread in these areas.31,38 No specific antiviral treatment or 
vaccine is currently available.
Genetic mutation of existing viruses  
and immunosuppression
Influenza viruses
Influenza viruses typically are thought of as respiratory 
disease–causing agents. However, their ability to undergo 
genetic mutation, antigenic drift, and affect host development 
as well as causing neurological symptoms suggests that they 
will continue to emerge as infections in the CNS. Influenza 
viruses are members of the family Orthomyxoviridae and 
typically are associated with symptoms of the flu.42  However, 
there can be neurological involvement as demonstrated  during 
epidemics, and potential involvement in neuropsychiatric 
disorders following prenatal exposure. There have been 
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reports of increasing incidence of influenza-associated 
encephalitis/encephalopathy,43 especially in children infected 
with influenza A (H1N1).44 Other clinical manifestations 
also may be observed during or following influenza A infec-
tions, including Reye’s syndrome, myelitis, Guillain-Barré 
 syndrome, and acute necrotizing encephalopathy.43,44 Prenatal 
influenza exposure also has been linked to the development 
of schizophrenia through analysis of a birth cohort of the 
Child Health and Development Study.45 Brown and col-
leagues used a case-control study based on this particular 
cohort to determine that there was a threefold elevation in 
risk for schizophrenia if there was exposure to influenza in 
the first half of gestation.46 Interestingly, the elevation of risk 
for schizophrenia was increased sevenfold when exposure 
occurred within the first trimester, whereas no increase was 
observed when influenza exposure occurred beyond the 
second half of gestation. Thus, the vulnerable stage for risk 
appears to be very early in gestation.46 What is not known at 
this time is the specific mechanism accounting for this risk. 
Investigations on influenza virus-infected pregnant mice 
have analyzed specific cellular populations in the brains of 
the offspring that appear to correlate in later life to decreased 
exploratory and social behavior, decreased contact with new 
objects in their environment, and an altered startle response 
to noise.47,48 Of the cellular changes in the offspring, there 
was a reduction in Cajal-Retzius cells in the cortex and hip-
pocampus that were reelin-positive.47 Reelin is involved in 
regulating neuronal migration and positioning of cells in the 
developing brain.49 In the same mice, there was a decrease in 
the cortical and hippocampal area but an increase in overall 
cortical pyramidal cell density.47 These studies suggest that 
influenza virus infection prenatally can have a dramatic result 
on fetal brain development that may manifest as psychiatric 
disease at later ages, although causality has yet to be proven 
conclusively for this involvement. Furthermore, there appears 
to be an increasing number of reported cases of neurologic 
sequelae following influenza epidemics.50 Often there is no 
specific treatment for infected individuals, although a num-
ber of drugs could be used to help treat and prevent the flu 
such as oseltamivir (Tamiflu®; Hoffman-La Roche, Basel, 
Switzerland) and zanamivir (Relenza®; GlaxoSmithKline, 
London, UK).51
JC virus
JC virus is a member of the Polyomaviridae family and causes 
progressive multifocal leukoencephalopathy (PML), a fatal 
neurological disease. This disease is observed principally in 
immunosuppressed or immunocompromised individuals who 
have low levels of cell-mediated immunity. In this regard, 
other infections such as those with human immunodeficiency 
virus (HIV) that result in an immunocompromised state 
as well as drug therapy for autoimmune diseases such as 
Crohn’s, multiple sclerosis, and rheumatoid arthritis promote 
an increased incidence of PML.52–55 As high percentages 
of the human population carry antibodies reactive to the 
JC virus, the virus is thought to reside latently in the body, 
systemically and in the CNS.56 Upon immunosuppression, 
reactivation of the virus is thought to occur leading to death 
of oligodendrocytes and destruction of myelin sheaths in the 
CNS. Neurological symptoms include weakness, paralysis, 
vision loss, impaired speech, and cognitive deterioration.56 
Thus, serious consideration must be made for individuals 
electing to be treated with many of the newer monoclonal 
antibody treatments such as natalizumab for Crohn’s disease 
resulting in variable degrees of immunosuppression.54
Herpes viruses
Herpes virus associated with immunocompetent individuals is 
human herpesvirus 6 (HHV6), a member of the Herpesviridae 
family. There are two variants (HHV6A and HHV6B). 
HHV6A is thought to be overall more virulent and neurotro-
pic, although HHV6B is found significantly in CNS disease.57 
For example, HHV6B is commonly found in childhood and 
has been associated with exanthem subitum (roseola infan-
tum) and meningoencephalitis.58,59 HHV6B also has been 
associated with infantile febrile illness with documented 
seizures.60 Interestingly, HHV6B has been associated more 
recently with fatal encephalitis in a number of cases following 
hematopoietic stem cell transplantation.61 Further, studies 
have found evidence of HHV6B in mesial temporal lobe 
epilepsy62,63 and multiple sclerosis.64  However, conclusive 
disease association with this virus in these diseases awaits 
further investigation as there is evidence of HHV6 variants 
in infection in normal human brain tissues.65  Commonly, 
the limbic areas of the brain were affected, including the 
amygdala, entorhinal cortex, and hippocampus, leading to 
a designation of posttransplant acute limbic encephalitis.61 
Ongoing research is investigating the roles of excitatory 
amino acids and inflammation in the pathological processes 
associated with HHV6 infection in the CNS.63,66 There is no 
specific treatment for HHV6 infections, but drugs used to 
treat other herpes infections (eg, ganciclovir) have been tried 
in severe infections.67
Herpes simplex virus 1 (HSV1) is another member of 
the Herpesviridae family. This virus is ubiquitous and often 
found latent in peripheral trigeminal ganglion neurons. 
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HSV1 may traffic into the CNS proper where the virus may 
remain latent or reactivate; reactivation can result in  serious 
acute encephalitis of the frontotemporal region of the brain 
in rare cases.68 Regarding neurodegenerative  disease, in 
particular Alzheimer’s disease (AD), studies have linked 
CNS viral infection to AD by analyzing HSV1 DNA in 
the brain,69–71 and anti-HSV1 antibodies in the CSF and 
sera of patients with AD.71,72 Furthermore, HSV1 has been 
 correlated to the apolipoprotein E ε4 risk for AD,73 and shown 
to bind to the amyloid precursor protein.74 HSV1 had been 
 demonstrated to code for a protein kinase involved with the 
phosphorylation of the tau protein.75,76 More recently, the 
virus has been shown to impair the autophagy pathway in 
cells infected in vitro.77 Thus, although great strides have been 
made in correlating this infection to the neurodegenerative 
process, ongoing and future studies must continue to focus 
on the mechanistic underpinnings of infection leading to the 
emerging nature of HSV1 in AD. With regard to potential 
therapy in AD, a recent study found that anti-HSV1 antiviral 
agents reduced Aβ and phosphorylated tau accumulations in 
HSV1-infected cells in vitro.78 Thus, potentially, anti-HSV1 
antiviral therapy could be used in HSV1-associated AD.
Bacteria
Emergence of bacterial infections in the CNS has been 
demonstrated (see Table 2). This review highlights some of 
the intracellular and extracellular bacteria contributing to 
disease in the CNS. Many of these bacteria use specific entry 
mechanisms into the CNS similar to those used by numer-
ous viruses, including bloodborne entry as well as potential 
neuroinvasion of peripheral and cranial nerves.79,80 With the 
advent of improved technology such as polymerase chain 
reaction (PCR) and real-time PCR, microbiome sequencing, 
and monoclonal antibodies to very specific epitopes, unique 
bacteria are being identified in the human population.81 
Intriguingly, many of these agents are being identified in 
areas of the body not thought to be initially infected such 
as the CNS and associated with chronic disease. Chronic 
disorders, more so than ever before, are being attributed to 
chronic infectious processes; emerging bacterial infection in 
the CNS may follow a similar pattern.
Intracellular bacteria
Orientia tsutsugamushi
Orientia tsutsugamushi is an obligate intracellular pathogen 
in the family Rickettsiaceae, and is the causative organism 
of scrub typhus.82 The natural vector and reservoir is the 
trombiculid mite.83 O. tsutsugamushi is a very common 
infection in Southeast Asia and in the western Pacific Rim 
countries. Because disease with this organism often presents 
as a febrile illness, a number of studies have investigated 
involvement with the CNS.80,84,85 The organism is thought 
to gain access to the CNS following infection of circulating 
monocytes and invasion of endothelial cells.80 Symptoms 
following entry to the CNS include nuchal rigidity, seizures, 
delirium, as well as meningismus and meningitis.80,84 In the 
endemic area of scrub typhus, O. tsutsugamushi should be 
considered a potential causative organism in mononuclear 
cell–involved meningitis as greater recognition has been 
demonstrated for the emergence of this Rickettsial organism 
in CNS disease.85 Treatment for infections with O. tsutsuga-
mushi typically includes using the antibiotics doxycycline 
and/or azithromycin.86
Ehrlichia chaffeensis
Ehrlichia chaffeensis, an obligate intracellular bacterium 
in the family Anaplasmataceae, causes human monocytic 
ehrlichiosis (HME). HME rates of infection are estimated to 
be 100–200 per 100,000 in endemic areas in the US, which 
include87 Mississippi, Oklahoma, Tennessee, Arkansas, and 
Maryland.88 Reports from other states are also being noted 
suggesting a continual emergence in the US.89 Importantly, 
as up to 66% of infections with E. chaffeensis are either 
minimally symptomatic or asymptomatic, the exact incidence 
of human infection may be higher.90 HME is transmitted 
by infection with the tick vector, Amblyomma americanum 
(Lone Star tick), which is prevalent in the southeast and 
south-central regions of the US.91 Neurologic manifestations 
occur in approximately 20% of patients infected with HME. 
Some patients may experience cranial nerve palsy and cogni-
tive deficits, and in children, there may be longer-term seque-
lae, including foot drop, fine motor impairment, and cognitive 
change.92 Pathogenesis in HME infections appears to result 
Table 2 Proposed bacteria emerging in central nervous system 
disease
Bacteria Condition/disease  
association
Bacterial  
family
Orientia tsutsugamushi Meningitis Rickettsiaceae
Ehrlichia chaffeensis Meningoencephalitis Anaplasmataceae
Chlamydia pneumoniae Alzheimer’s disease/ 
multiple sclerosis
Chlamydiaceae
Borrelia burgdorferi Neuroborreliosis/ 
Alzheimer’s disease
Spirochaetaceae
Helicobacter pylori Parkinson’s disease Helicobacteraceae
Note: Although some of these organisms have been associated with acute and/
or chronic CNS disease entities, causality in numerous instances remains to be 
proven.
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from the inability of the cell to undergo  phagolysosome 
fusion,93 and to the immune-mediated pathology that results 
especially with significant expansion of cytotoxic CD8+ 
T cells and their production of tumor necrosis factor-alpha 
and interferon-gamma.94 Since 1987, HME has become a 
serious and prevalent tick-borne cause of human infections 
in the US.95 With the ever-expanding niche for ticks and 
animal reservoirs such as white-tailed deer, and their increas-
ing encounters with the resident human population, HME 
will continue to emerge as a major cause of vector-borne 
meningoencephalitis. Treatment for HME typically involves 
a course of antibiotic therapy with doxycycline.96
Chlamydia pneumoniae
Chlamydia pneumoniae (Cpn), an obligate intracellular 
bacterium in the family Chlamydiaceae, typically infects 
the human respiratory tract often resulting in a chronic 
cough, little sputum production, and a low-grade fever.97 The 
organism has been shown to enter the systemic circulation 
following infection of monocytes surveilling lung tissues.98 
The ability to spread systemically may be one reason this 
bacterium has been identified in nonrespiratory conditions, 
including AD and multiple sclerosis (MS). Associations 
of Cpn with AD99 and MS100 were first reported in 1998. 
Over the last several years, other reports have strengthened 
these associations,101,102 but more evidence is required 
to demonstrate proof of causality. In this regard, studies 
have addressed and continue to address Cpn infection in 
vivo in diseased populations and in animal models, and in 
vitro in infected tissue cultures. What is becoming clearer 
is that Cpn can enter and remain in the CNS as a chronic/
persistent infection,103,104 and may be a major stimulus for 
neuroinflammation.105 Furthermore, infection of the brain 
may involve not only monocyte delivery but also infection 
of the olfactory cranial nerve following exposure in the nose. 
Evidence for this pathway follows from analysis of olfactory 
tissues from patients with AD,99 as well as animal models.103 
Molecular analyses following Cpn infection in cell culture 
are addressing specific pathways known to be disrupted or 
modified in AD. For example, modification of apoptosis106 
and autophagy pathways as well as inflammatory pathways 
following infection are being studied to better understand 
the molecular pathogenesis of infection-mediated disease. In 
effect, continued correlation of CNS infection with Cpn and 
AD and MS may reflect the relatively newly recognized emer-
gence of chronic infection with major neurological diseases. 
Treatment for community-acquired pneumonias, including 
those caused by Cpn, typically involves antibiotics such as 
doxycycline, azithromycin, and/or  fluoroquinolones.107 One 
clinical trial with some positive results has been performed 
using the anti-Cpn antibiotics doxycycline and rifampin in 
treating patients with AD.108
Extracellular bacteria
Borrelia burgdorferi
Borrelia burgdorferi organisms are spirochetes in the family 
of Spirochaetaceae that cause borreliosis or Lyme disease, 
a zoonotic, vector-borne disease transmitted primarily by 
ticks such as Ixodes scapularis in North America. Typically, 
a localized infection occurs following the tick bite, and 
evasion of the immune system ensues once in the host.109 
B. burgdorferi infects monocytes that are thought to dis-
seminate the organism into the CNS through the blood-brain 
barrier.109 Once the organism is in the brain, a chronic infec-
tion may ensue in which neuroborreliosis and/or Alzheimer’s 
disease may become manifest.110 Symptoms of nervous 
system involvement may include meningoradiculitis, cranial 
nerve abnormalities, and altered mental status.109 Evidence 
for involvement in AD comes from analysis of postmortem 
AD brain tissues in which Borrelia was identified.111 Further 
studies in vitro have supported these findings by demonstrat-
ing that infection of neurons, astrocytes, and microglial cells 
led to the production and aggregation of amyloid as well as 
tangle-like structures within nerve cells.112 In this regard, 
bacterial products from the organism such as lipopolysac-
charide have been shown to initiate a strong response by 
neuronal and glial cells implicating Borrelia with AD.112 
At this time, causality has not been determined regarding 
this infection and AD pathogenesis; however, the infection 
induction of beta amyloid processing and tau hyperphos-
phorylation comparable to what is observed in AD makes 
B. burgdorferi a candidate infection as a stimulus for CNS 
damage.112 Neuroborreliosis is typically treated with intra-
venous antibiotics that cross the blood-brain barrier such as 
ceftriaxone and doxycycline.113
Helicobacter pylori
Helicobacter pylori are members of the Helicobacteraceae 
family. Infection with this organism in the stomach is consid-
ered the major cause of peptic and gastric ulcers.114 H. pylori 
infection has been postulated to play a role in idiopathic 
Parkinson’s (IP) disease.115 This follows from analysis of 
common immunological manifestations, epidemiological 
similarities of familial aggregation and linkage with a com-
mon source of drinking water, and the demonstration that 
the infection can be passed between siblings in childhood 
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and between spouses.115 Probands with IP and siblings share 
a threefold increase in odds of seropositivity for antibodies 
against H. pylori urease.116 Furthermore, a discriminant index 
for the presence/absence of diagnosed Parkinsonism has 
been derived from Western blot serum H. pylori antibody 
profiles in subjects with and without IP that contained known 
pathogenicity markers.117 The persistence of antibody against 
cytotoxin-associated antigen (CagA) increased the predicted 
probability of Parkinsonism by 80 years of age fivefold.117 
More recently, a population-based study of patients with 
Parkinson’s in Denmark suggested chronic H. pylori infec-
tion and/or gastritis either contributed to Parkinson’s disease 
(PD) or that these are PD-related pathologies that precede 
motor dysfunction.118 Mechanistically, chronic inflamma-
tion and autoimmune modulation have been proposed as 
contributors to IP with H. pylori infection.115 Some evidence 
for immune modulation has been demonstrated in vitro as 
H. pylori has been shown to suppress T-cell proliferation,119 
and in infected individuals, H. pylori-specific T-regs have 
been shown to suppress T-cell responses.120 Extraintestinal 
influence in IP may be more prominent with CagA-positive 
strains of H. pylori regarding autoimmune mechanisms.121 
The exact relationship between H. pylori infection and IP 
has yet to be determined. What is becoming clearer is that 
relationships may exist between the gut and brain such that 
infectious components arising in the gastrointestinal tract 
affect brain function. Treatment for H. pylori gastric infec-
tion typically includes the combination of two antibiotics 
such as clarithromycin and metronidazole and a proton pump 
inhibitor such as omeprazole, sometimes together with a 
bismuth compound.122
Conclusion
Emerging viruses and bacteria in the CNS are significant 
contributors to increased morbidity and mortality in human 
populations worldwide. Recognition of this emergence is 
vital in developing adequate preventive regimens, diagnostic 
procedures, and treatment measures. Clinicians and infectious 
disease researchers must be aware of acute and chronic pro-
cesses of infectious origin that may be insulting the nervous 
system. Neurological diseases not typically thought to be 
infectious must be examined fully for microbial involvement 
and analyzed for direct and indirect associations. We are chal-
lenged to develop methodology that will clearly detect and 
identify infectious agents in the CNS. Finally, understanding 
the relationships between systemic infection and neurologic 
disease is vital, and may provide clues leading to better pre-
dictability, treatment, and prevention of CNS diseases.
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